Remission maintenance therapy in acute myelogenous leukemia.
Because no conclusive evidence as to the efficacy of maintenance chemotherapy in acute myelogenous leukemia (AML) existed, a study to obtain such information was done. Twenty-six adult patients with AML in whom complete remission had been achieved following induction chemotherapy were randomly assigned to receive either maintenance chemotherapy consisting of cytarabine and 6-thioguanine for two days each month or to receive no maintenance therapy. The data showed a significant difference in remission duration between the two groups, with median remission lengths for the maintained and unmaintained groups being 10.3 and 6.7 months, respectively (p<.05). In 46 percent of the maintained patients there were remissions lasting longer than 11 months, whereas in none of the unmaintained patients was there such a prolonged remission. No significant drug-induced toxicity was observed. That the prolonged exposure to these chemotherapeutic agents, which were also used in our induction program, did not adversely affect the rate of successful reinduction therapy was shown by identical 50 percent complete remission rates for second inductions in both groups. In patients with palpable splenomegaly at the time of diagnosis, there was no prolongation of remission with maintenance therapy. These data indicate the potential utility of maintenance chemotherapy for prolonging remission duration in acute myelogenous leukemia.
D000293:Adolescent; D000328:Adult; D000368:Aged; D003561:Cytarabine / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use
D003561:Cytarabine; D013866:Thioguanine
Lancet. 1975 Oct 4;2(7936):621-4
52000
N Engl J Med. 1976 Jan 8;294(2):75-80
53787
JAMA. 1976 Mar 8;235(10):1021-5
946184
Cancer. 1975 Aug;36(2):775-95
1057450
Br J Haematol. 1976 Feb;32(2):145-9
1061617
Cancer. 1975 Sep;36(3):855-60
1182675
Cancer Res. 1972 Dec;32(12):2593-607
4118763
Lancet. 1973 Mar 10;1(7802):534-8
4119962
JAMA. 1968 May 13;204(7):574-9
4296700
Calif Med. 1972 Dec;117(6):1-11
4508367
Cancer. 1972 Dec;30(6):1572-82
4509106
Cancer. 1973 Aug;32(2):286-93
4516214
Semin Hematol. 1974 Jan;11(1):25-39
4520529
Arch Intern Med. 1974 Feb;133(2):260-6
4521468
Cancer. 1974 Feb;33(2):427-34
4521471
Blood. 1974 Sep;44(3):375-83
4527645
Blood. 1968 Oct;32(4):507-23
4879053
Presse Med. 1970 Jan 31;78(6):253-6
4984925
Cancer. 1969 May;23(5):1019-32
5252232
Nat New Biol. 1971 Sep 22;233(38):109-10
5285962
Cancer Chemother Rep. 1967 Jun;51(3):125-65
6043735
Cancer Chemother Rep. 1964 Nov;42:25-8
14226126
Biometrika. 1965 Jun;52:203-23
14341275
J Clin Invest. 1967 Aug;46(8):1356-63
16695924